Analyst consensus rating
Climb Bio Analyst Rating: Strong Buy
CLYM is rated Strong Buy by 14 analysts with a $22.86 target. As of 2026-08-26.
Direct answer
Climb Bio's consensus rating is Strong Buy.
14 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $22.86.
Forecast evidence checked August 26, 2026.
Get free Climb Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $17.84
- Average price target
- $22.86
- High price target
- $35.00
- Low price target
- $18.00
- Low target gap
- +0.9%
- Target upside
- +28.1%
- High target gap
- +96.2%
- Target range width
- 95.3%
- Consensus rating
- Strong Buy
- Analysts
- 14
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Climb Bio?
Climb Bio has a verified Strong Buy consensus. The same dataset has an average price target of $22.86.
How far are Climb Bio's low and high targets from the recorded price?
The low target implies +0.9%, while the high target implies +96.2%.
How many analysts are included in Climb Bio's consensus?
The verified consensus includes 14 analysts.
How is Climb Bio's target upside or downside calculated?
The average target of $22.86 is divided by the recorded price of $17.84, then one is subtracted to produce +28.1%. This does not guarantee a future return.
When was Climb Bio's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.